Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL‐101 study
Abstract Parsaclisib, a potent and selective phosphatidylinositol 3 kinase δ inhibitor, has been investigated for the treatment of B‐cell malignancies and studied in patients with autoimmune diseases and myelofibrosis. The CITADEL‐101 study (NCT02018861) assessed safety, tolerability, and preliminar...
Main Authors: | Jia Li, Xiaohua Gong, Xing Liu, Xiang Liu, Ke Szeto, Xuejun Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-04-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.1165 |
Similar Items
-
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyResearch in context
by: Marek Trněný, et al.
Published: (2023-09-01) -
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyResearch in context
by: Pier Luigi Zinzani, et al.
Published: (2023-08-01) -
Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes
by: Khaled Aburisheh, et al.
Published: (2023-03-01) -
24 h Holter ECG Monitoring of Patients with Rheumatoid Arthritis—A Potential Role for a Precise Evaluation of QT Interval Duration and Associated Arrhythmic Complications
by: Elena E. Saramet, et al.
Published: (2022-03-01) -
Diagnostic Accuracy of the Standing Test in Adults Suspected for Congenital Long‐QT Syndrome
by: Arja S. Vink, et al.
Published: (2023-07-01)